Insider trading

Period: 120 months Stock: FULC Type of trade: Sold × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

62 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

62 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

62 decisions over 120 months Remove this filter
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

62 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
62 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
62 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

62 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
26 Jun 2026
Ezekowitz Alan Director
Sold at will
$65.61K 18,000 at 3.65
62.2%
Sold half or more
2 Feb 2026
Gould Robert J Director
Sold at will
$160.86K 15,000 at 10.72
3.2%
Not planned
2 Jan 2026
Gould Robert J Director
Sold at will
$178.09K 15,000 at 11.87
3.1%
Not planned
15 Dec 2025
Oltmans Curtis Gale Chief Legal Officer
Sold at will
$44.60K 3,452 at 12.92
25.2%
Not planned
8 Dec 2025
RA CAPITAL MANAGEMENT, L.P. 10% owner · indirect
Sold at will 3×
$58.38M 4,175,139 at 13.98
40.8%
Not planned
19 Nov 2025
Gould Robert J Director
Sold at will
$165.50K 15,000 at 11.03
3.0%
Not planned
8 May 2025
Tourangeau Greg Principal Accounting Officer
Sold at will
$2.52K 498 at 5.06
3.4%
Not planned
7 May 2024
Tourangeau Greg Principal Accounting Officer
Sold at will
$1.83K 236 at 7.76
2.0%
Not planned
8 Mar 2024
Tourangeau Greg Vice President, Finance
Sold at will
$57.22K 4,884 at 11.72
29.3%
Not planned
10 May 2023
Tourangeau Greg Principal Accounting Officer
Sold at will
$695.10 210 at 3.31
1.3%
Not planned
13 Jan 2023
Gould Robert J Interim President & CEO
Sold, plan not stated
$101.49K 6,766 at 15.00
1.3%
7 Jun 2022
Gould Robert J Director
Sold, plan not stated
$577.89K 71,435 at 8.09
12.4%
6 Jun 2022
Gould Robert J Director
Sold, plan not stated
$197.59K 24,382 at 8.10
4.6%
3 Jun 2022
Gould Robert J Director
Sold, plan not stated
$203.06K 25,551 at 7.95
4.8%
2 Jun 2022
Gould Robert J Director
Sold, plan not stated
$132.16K 16,689 at 7.92
3.2%
7 Apr 2022
Gould Robert J Director
Sold, plan not stated
$135.23K 5,631 at 24.02
1.1%
5 Apr 2022
Gould Robert J Director
Sold, plan not stated
$1.27M 52,552 at 24.26
9.4%
4 Apr 2022
Gould Robert J Director
Sold, plan not stated
$173.75K 7,235 at 24.02
1.4%
1 Apr 2022
Gould Robert J Director
Sold, plan not stated
$828.16K 34,464 at 24.03
6.4%
11 Aug 2021
Stuart Bryan See Remarks
Sold, plan not stated
$665.00K 28,000 at 23.75
100%
Sold half or more
10 Aug 2021
Stuart Bryan See Remarks
Sold, plan not stated
$560.00K 32,000 at 17.50
100%
Sold half or more
10 Aug 2021
Moxham Christopher Chief Scientific Officer
Sold, plan not stated
$559.28K 31,071 at 18.00
100%
Sold half or more
10 Aug 2021
Moxham Christopher Chief Scientific Officer
Sold, plan not stated
$352.14K 20,714 at 17.00
100%
Sold half or more
16 Mar 2021
Gould Robert J See Remarks
Sold, plan not stated
$9.81K 789 at 12.43
0.2%
15 Mar 2021
Gould Robert J See Remarks
Sold, plan not stated
$111.77K 9,211 at 12.13
1.8%
22 Feb 2021
Thomson Peter G. VP Finance & Accounting
Sold, plan not stated
$73.58K 5,000 at 14.72
24.7%
16 Feb 2021
Gould Robert J See Remarks
Sold, plan not stated 2×
$117.20K 8,215 at 14.27
1.6%
21 Jan 2021
Thomson Peter G. VP Finance & Accounting
Sold, plan not stated
$92.50K 6,607 at 14.00
30.3%
20 Jan 2021
Gould Robert J See Remarks
Sold, plan not stated
$120.83K 10,000 at 12.08
1.9%
8 Jul 2020
Wallace Owen B. Chief Scientific Officer
Sold, plan not stated
$59.02K 2,951 at 20.00
2.3%
8 Jul 2020
Gould Robert J See Remarks
Sold, plan not stated
$50.00K 2,500 at 20.00
0.5%
1 Jul 2020
Cadavid Diego SVP Clinical Development
Sold, plan not stated
$19.60K 1,071 at 18.30
1.6%
30 Jun 2020
Wallace Owen B. Chief Scientific Officer
Sold, plan not stated
$2.82K 141 at 20.00
0.1%
25 Jun 2020
Gould Robert J See Remarks
Sold, plan not stated
$51.99K 2,500 at 20.80
0.5%
25 Jun 2020
Cadavid Diego SVP Clinical Development
Sold, plan not stated
$32.10K 1,459 at 22.00
2.1%
10 Jun 2020
Cadavid Diego SVP Clinical Development
Sold, plan not stated
$8.82K 401 at 22.00
0.6%
9 Jun 2020
Gould Robert J See Remarks
Sold, plan not stated
$3.12K 156 at 20.00
0.0%
5 Jun 2020
Gould Robert J See Remarks
Sold, plan not stated
$69.25K 3,433 at 20.17
0.6%
5 Jun 2020
Cadavid Diego SVP Clinical Development
Sold, plan not stated
$9.10K 451 at 20.18
0.7%
4 Jun 2020
Gould Robert J See Remarks
Sold, plan not stated
$26.06K 1,300 at 20.04
0.2%
4 Jun 2020
Cadavid Diego SVP Clinical Development
Sold, plan not stated
$4.53K 226 at 20.05
0.3%
3 Jun 2020
Gould Robert J See Remarks
Sold, plan not stated
$30.19K 1,500 at 20.13
0.3%
3 Jun 2020
Cadavid Diego SVP Clinical Development
Sold, plan not stated
$6.82K 338 at 20.18
0.5%
2 Jun 2020
Gould Robert J See Remarks
Sold, plan not stated
$55.94K 2,797 at 20.00
0.5%
2 Jun 2020
Cadavid Diego SVP Clinical Development
Sold, plan not stated
$900.00 45 at 20.00
0.1%
1 Jun 2020
Gould Robert J See Remarks
Sold, plan not stated
$100.00 5 at 20.00
0.0%
29 May 2020
Gould Robert J See Remarks
Sold, plan not stated
$27.91K 1,390 at 20.08
0.3%
29 May 2020
Cadavid Diego SVP Clinical Development
Sold, plan not stated
$4.01K 200 at 20.04
0.3%
28 May 2020
Wallace Owen B. Chief Scientific Officer
Sold, plan not stated
$44.64K 2,232 at 20.00
1.7%
28 May 2020
Gould Robert J See Remarks
Sold, plan not stated
$38.39K 1,919 at 20.01
0.3%
Showing 1–50 of 62. Page 1 of 2 Older →